These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28197316)

  • 1. Design and Synthesis of Novel, Selective GPR40 AgoPAMs.
    Plummer CW; Clements MJ; Chen H; Rajagopalan M; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Nolting AF; Orr R; Christensen M; Campeau LC; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Nargund R; Howard AD; Colletti SL
    ACS Med Chem Lett; 2017 Feb; 8(2):221-226. PubMed ID: 28197316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.
    Pio B; Chobanian HR; Guo Y; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Ashley E; Orr R; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Samuel K; Chen Q; Shang J; Lamca J; Ehrhart J; Nargund R; Howard AD; Colletti SL
    Bioorg Med Chem Lett; 2019 Jul; 29(14):1842-1848. PubMed ID: 31109791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
    Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
    PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR40 reduces food intake and body weight through GLP-1.
    Gorski JN; Pachanski MJ; Mane J; Plummer CW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Cheewatrakoolpong B; Howard AD; Colletti SL; Trujillo ME
    Am J Physiol Endocrinol Metab; 2017 Jul; 313(1):E37-E47. PubMed ID: 28292762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
    Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
    ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities.
    Jurica EA; Wu X; Williams KN; Haque LE; Rampulla RA; Mathur A; Zhou M; Cao G; Cai H; Wang T; Liu H; Xu C; Kunselman LK; Antrilli TM; Hicks MB; Sun Q; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Khandelwal P; Wilkes JJ; Zinker BA; Robertson DG; Janovitz EB; Galella M; Li YX; Li J; Ramar T; Jalagam PR; Jayaram R; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA
    Bioorg Med Chem; 2023 May; 85():117273. PubMed ID: 37030194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs.
    Chen HY; Plummer CW; Xiao D; Chobanian HR; DeMong D; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Di Salvo J; Thomas-Fowlkes B; Souza S; Tatosian DA; Chen Q; Hafey MJ; Houle R; Nolting AF; Orr R; Ehrhart J; Weinglass AB; Tschirret-Guth R; Howard AD; Colletti SL
    ACS Med Chem Lett; 2018 Jul; 9(7):685-690. PubMed ID: 30034601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
    Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
    PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.
    Brown SP; Dransfield P; Vimolratana M; Zhu L; Luo J; Zhang J; Jiao X; Pattaropong V; Wong S; Zhuang R; Swaminath G; Houze JB; Lin DC
    ACS Med Chem Lett; 2018 Jul; 9(7):757-760. PubMed ID: 30034614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats.
    Tsuda N; Kawaji A; Sato T; Takagi M; Higashi C; Kato Y; Ogawa K; Naba H; Ohkouchi M; Nakamura M; Hosaka Y; Sakaki J
    Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40.
    Lu J; Byrne N; Wang J; Bricogne G; Brown FK; Chobanian HR; Colletti SL; Di Salvo J; Thomas-Fowlkes B; Guo Y; Hall DL; Hadix J; Hastings NB; Hermes JD; Ho T; Howard AD; Josien H; Kornienko M; Lumb KJ; Miller MW; Patel SB; Pio B; Plummer CW; Sherborne BS; Sheth P; Souza S; Tummala S; Vonrhein C; Webb M; Allen SJ; Johnston JM; Weinglass AB; Sharma S; Soisson SM
    Nat Struct Mol Biol; 2017 Jul; 24(7):570-577. PubMed ID: 28581512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
    ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
    Luo J; Swaminath G; Brown SP; Zhang J; Guo Q; Chen M; Nguyen K; Tran T; Miao L; Dransfield PJ; Vimolratana M; Houze JB; Wong S; Toteva M; Shan B; Li F; Zhuang R; Lin DC
    PLoS One; 2012; 7(10):e46300. PubMed ID: 23056280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
    Wang Y; Liu JJ; Dransfield PJ; Zhu L; Wang Z; Du X; Jiao X; Su Y; Li AR; Brown SP; Kasparian A; Vimolratana M; Yu M; Pattaropong V; Houze JB; Swaminath G; Tran T; Nguyen K; Guo Q; Zhang J; Zhuang R; Li F; Miao L; Bartberger MD; Correll TL; Chow D; Wong S; Luo J; Lin DC; Medina JC
    ACS Med Chem Lett; 2013 Jun; 4(6):551-5. PubMed ID: 24900707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.